Section 5 of 6

Economic information and modeling report

4 evidence topics · 3 sources

Modeling overview

Summary

The economic models identified here concern amivantamab plus chemotherapy rather than Zipalertinib. A U.S. payer partitioned-survival model reported an ICER of $432,401.16 per QALY. Canada’s Drug Agency reported an ICER of $233,922 per QALY for amivantamab plus carboplatin-pemetrexed versus platinum-based chemotherapy. These comparator analyses do not establish Zipalertinib acquisition cost, cost-effectiveness, or budget impact.

Canada’s Drug Agency reimbursement recommendation: first-line amivantamab plus carboplatin-pemetrexed

“The ICER for amivantamab plus carboplatin-pemetrexed is $233,922 per QALY gained when compared with platinum-based chemotherapy alone.” (opens the source at this quote in a new tab)

U.S. payer model: scenario and sensitivity analyses

“In the scenario analysis, the results showed that the ICERs were $263,680.69/QALY and $418,416.35/QALY when different utility values and 10-year time horizons were adopted, respectively.” (opens the source at this quote in a new tab)
“For PSA, the probability that amivantamab plus chemotherapy would be cost-effective was 0% if the willingness-to-pay (WTP) threshold was $150,000/QALY.” (opens the source at this quote in a new tab)
“The diagram shows the top 15 model parameters that influence the results, with the PD state utility value, the unit price of amivantamab, and the PFS state utility value identified as having the most significant impact.” (opens the source at this quote in a new tab)
“When we increased the WTP threshold to $200,000/QALY, chemotherapy remained a cost-effective option 99.7% of the time.” (opens the source at this quote in a new tab)

U.S. payer model: cost perspective and inputs

“Our study considered only direct medical care costs from a US payer’s perspective, covering costs associated with treatment regimens, disease management, follow-up treatments, end-of-life care, and the management of adverse events (AEs).” (opens the source at this quote in a new tab)
“Furthermore, since EGFR mutation testing is essential for identifying patients with EGFR exon 20 insertion mutation-positive NSCLC, the cost of performing EGFR gene analysis was considered the overall cost.” (opens the source at this quote in a new tab)
“All costs were presented in 2023 USD” (opens the source at this quote in a new tab)

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.